Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Other Non-Current Liabilities (2019 - 2024)

Historic Other Non-Current Liabilities for Lipocine (LPCN) over the last 7 years, with Q3 2024 value amounting to $3586.0.

  • Lipocine's Other Non-Current Liabilities fell 8781.93% to $3586.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $3586.0, marking a year-over-year decrease of 8781.93%. This contributed to the annual value of $17166.0 for FY2023, which is 9253.18% down from last year.
  • Latest data reveals that Lipocine reported Other Non-Current Liabilities of $3586.0 as of Q3 2024, which was down 8781.93% from $141668.0 recorded in Q2 2024.
  • In the past 5 years, Lipocine's Other Non-Current Liabilities ranged from a high of $50.5 million in Q1 2021 and a low of $3586.0 during Q3 2024
  • For the 5-year period, Lipocine's Other Non-Current Liabilities averaged around $17.5 million, with its median value being $19.6 million (2020).
  • As far as peak fluctuations go, Lipocine's Other Non-Current Liabilities skyrocketed by 14713.42% in 2021, and later tumbled by 9991.34% in 2023.
  • Over the past 5 years, Lipocine's Other Non-Current Liabilities (Quarter) stood at $20.0 million in 2020, then crashed by 96.02% to $795796.0 in 2021, then tumbled by 71.12% to $229856.0 in 2022, then plummeted by 92.53% to $17166.0 in 2023, then crashed by 79.11% to $3586.0 in 2024.
  • Its Other Non-Current Liabilities stands at $3586.0 for Q3 2024, versus $141668.0 for Q2 2024 and $57238.0 for Q1 2024.